Cargando…
Hyperlipidemia, statin use and dengue severity
Multiple in vitro and mice model studies suggest statins may attenuate dengue severity. However, little is known about statin use and dengue severity in adult dengue patients with hyperlipidemia. We conducted a retrospective cohort study from 2004–2008 and 2012–2013 in Tan Tock Seng Hospital, Singap...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6249290/ https://www.ncbi.nlm.nih.gov/pubmed/30464247 http://dx.doi.org/10.1038/s41598-018-35334-2 |
_version_ | 1783372714684186624 |
---|---|
author | Chia, Po Ying Htun, Htet Lin Ling, Wei Ping Leo, Yee Sin Yeo, Tsin Wen Lye, David Chien Boon |
author_facet | Chia, Po Ying Htun, Htet Lin Ling, Wei Ping Leo, Yee Sin Yeo, Tsin Wen Lye, David Chien Boon |
author_sort | Chia, Po Ying |
collection | PubMed |
description | Multiple in vitro and mice model studies suggest statins may attenuate dengue severity. However, little is known about statin use and dengue severity in adult dengue patients with hyperlipidemia. We conducted a retrospective cohort study from 2004–2008 and 2012–2013 in Tan Tock Seng Hospital, Singapore on adult dengue patients with hyperlipidemia, comparing those with and without statin usage at hospitalization in terms of primary outcome of dengue hemorrhagic fever (DHF) or shock syndrome (DSS), and severe dengue (SD). Of 13,975 subjects screened, 257 dengue patients were included; 191 (74.3%) were statin users and 66 (25.7%) were non-users. Compared with non-users, statin use was not associated with decreased risk of DHF/DSS (adjusted risk ratio [aRR] = 0.66, 95%confidence interval [CI]: 0.41–1.08, P = 0.10) and SD (aRR = 1.43, 95%CI: 0.84–2.43, P = 0.19). Therefore, statin usage had minimal effect on dengue severity in our study population in Singapore. |
format | Online Article Text |
id | pubmed-6249290 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-62492902018-11-28 Hyperlipidemia, statin use and dengue severity Chia, Po Ying Htun, Htet Lin Ling, Wei Ping Leo, Yee Sin Yeo, Tsin Wen Lye, David Chien Boon Sci Rep Article Multiple in vitro and mice model studies suggest statins may attenuate dengue severity. However, little is known about statin use and dengue severity in adult dengue patients with hyperlipidemia. We conducted a retrospective cohort study from 2004–2008 and 2012–2013 in Tan Tock Seng Hospital, Singapore on adult dengue patients with hyperlipidemia, comparing those with and without statin usage at hospitalization in terms of primary outcome of dengue hemorrhagic fever (DHF) or shock syndrome (DSS), and severe dengue (SD). Of 13,975 subjects screened, 257 dengue patients were included; 191 (74.3%) were statin users and 66 (25.7%) were non-users. Compared with non-users, statin use was not associated with decreased risk of DHF/DSS (adjusted risk ratio [aRR] = 0.66, 95%confidence interval [CI]: 0.41–1.08, P = 0.10) and SD (aRR = 1.43, 95%CI: 0.84–2.43, P = 0.19). Therefore, statin usage had minimal effect on dengue severity in our study population in Singapore. Nature Publishing Group UK 2018-11-21 /pmc/articles/PMC6249290/ /pubmed/30464247 http://dx.doi.org/10.1038/s41598-018-35334-2 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Chia, Po Ying Htun, Htet Lin Ling, Wei Ping Leo, Yee Sin Yeo, Tsin Wen Lye, David Chien Boon Hyperlipidemia, statin use and dengue severity |
title | Hyperlipidemia, statin use and dengue severity |
title_full | Hyperlipidemia, statin use and dengue severity |
title_fullStr | Hyperlipidemia, statin use and dengue severity |
title_full_unstemmed | Hyperlipidemia, statin use and dengue severity |
title_short | Hyperlipidemia, statin use and dengue severity |
title_sort | hyperlipidemia, statin use and dengue severity |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6249290/ https://www.ncbi.nlm.nih.gov/pubmed/30464247 http://dx.doi.org/10.1038/s41598-018-35334-2 |
work_keys_str_mv | AT chiapoying hyperlipidemiastatinuseanddengueseverity AT htunhtetlin hyperlipidemiastatinuseanddengueseverity AT lingweiping hyperlipidemiastatinuseanddengueseverity AT leoyeesin hyperlipidemiastatinuseanddengueseverity AT yeotsinwen hyperlipidemiastatinuseanddengueseverity AT lyedavidchienboon hyperlipidemiastatinuseanddengueseverity |